MicroRNAs as pathophysiological targets: An emerging nexus for personalized medicine in heart failure?

Trends in Cardiovascular Medicine

Volumn 26, Issue 2, 2016, Pages 111-114

  Feinberg, Mark W ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 1; MICRORNA 126; MICRORNA 132; MICRORNA 155; MICRORNA 199B; MICRORNA 208; MICRORNA 210; MICRORNA 212; MICRORNA 214; MICRORNA 24; MICRORNA 34; MICRORNA 92A; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; EDITORIAL; GENE TARGETING; HEART FAILURE; HEART INFARCTION; HEART MUSCLE INJURY; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MYOCARDITIS; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; GAP JUNCTION; PROGNOSIS;

GAP JUNCTIONS; HEART FAILURE; HUMANS; MICRORNAS; PRECISION MEDICINE; PROGNOSIS;

EID: 84959039906     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2015.06.001     Document Type: Editorial

References (25)

1. Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E., Drazner M.H., et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013, 128:e240-e327.
2. McMurray J.J., Petrie M.C., Murdoch D.R., Davie A.P. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J 1998, (Suppl. 19):P9-P16.
3. Duygu B., de Windt L.J., da Costa Martins P.A. Targeting microRNAs in Heart Failure. Trends Cardiovasc Med 2015, 26:99-110.
4. Palardy M., Ducharme A., O'Meara E. Inhibiting the renin-angiotensin system with ACE Inhibitors or ARBs after MI. Curr Heart Fail Rep 2007, 4:190-197.
5. Vaughan D.E., Pfeffer M.A. Post-myocardial infarction ventricular remodeling: animal and human studies. Cardiovasc Drugs Ther 1994, 8:453-460.
6. van Rooij E., Sutherland L.B., Thatcher J.E., DiMaio J.M., Naseem R.H., Marshall W.S., et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 2008, 105:13027-13032.
7. Roncarati R., Viviani Anselmi C., Losi M.A., Papa L., Cavarretta E., Da Costa Martins P., et al. Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2014, 63:920-927.
8. van Rooij E., Sutherland L.B., Liu N., Williams A.H., McAnally J., Gerard R.D., et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 2006, 103:18255-18260.
9. Duisters R.F., Tijsen A.J., Schroen B., Leenders J.J., Lentink V., van der Made I., et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 2009, 104:170-178. [176p following 178].
10. Liu N., Bezprozvannaya S., Williams A.H., Qi X., Richardson J.A., Bassel-Duby R., et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 2008, 22:3242-3254.
11. Pan Z., Sun X., Shan H., Wang N., Wang J., Ren J., et al. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-beta1 pathway. Circulation 2012, 126:840-850.
12. Bonauer A., Carmona G., Iwasaki M., Mione M., Koyanagi M., Fischer A., et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009, 324:1710-1713.
13. Boon R.A., Iekushi K., Lechner S., Seeger T., Fischer A., Heydt S., et al. MicroRNA-34a regulates cardiac ageing and function. Nature 2013, 495:107-110.
14. Fiedler J., Jazbutyte V., Kirchmaier B.C., Gupta S.K., Lorenzen J., Hartmann D., et al. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 2011, 124:720-730.
15. Icli B., Wara A.K., Moslehi J., Sun X., Plovie E., Cahill M., et al. MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling. Circ Res 2013, 113:1231-1241.
16. Hu S., Huang M., Li Z., Jia F., Ghosh Z., Lijkwan M.A., et al. MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 2010, 122:S124-S131.
17. Wang S., Aurora A.B., Johnson B.A., Qi X., McAnally J., Hill J.A., et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008, 15:261-271.
18. Icli B., Dorbala P., Feinberg M.W. An emerging role for the miR-26 family in cardiovascular disease. Trends Cardiovasc Med 2014, 24:241-248.
19. da Costa Martins PA, Salic K, Gladka MM, Armand AS, Leptidis S, el Azzouzi H, et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat Cell Biol 12: 1220-7.
20. el Azzouzi H., Leptidis S., Dirkx E., Hoeks J., van Bree B., Brand K., et al. The hypoxia-inducible microRNA cluster miR-199a approximately 214 targets myocardial PPARdelta and impairs mitochondrial fatty acid oxidation. Cell Metab 2013, 18:341-354.
21. Castaldi A., Zaglia T., Di Mauro V., Carullo P., Viggiani G., Borile G., et al. MicroRNA-133 modulates the beta1-adrenergic receptor transduction cascade. Circ Res 2014, 115:273-283.
22. Ikeda S., He A., Kong S.W., Lu J., Bejar R., Bodyak N., et al. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol 2009, 29:2193-2204.
23. Montgomery R.L., Hullinger T.G., Semus H.M., Dickinson B.A., Seto A.G., Lynch J.M., et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 2011, 124:1537-1547.
24. Heymans S., Corsten M.F., Verhesen W., Carai P., van Leeuwen R.E., Custers K., et al. Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation 2013, 128:1420-1432.
25. Janssen H.L., Reesink H.W., Lawitz E.J., Zeuzem S., Rodriguez-Torres M., Patel K., et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013, 368:1685-1694.